Institute of Bioorganic Chemistry

http://iboch.bas-net.by/  

Medicinal preparations with antitumor and antiviral activity and initial nucleosides for their creation

COUNTRY OF ORIGIN

Belarus

IDENTIFIER

BO4703

PUBLISHED

2022-01-14

LAST UPDATE

2022-01-15

DEADLINE

Linked profile in other language
Responsible
Aleksej Yantsevich
+375 17 357 8761
info@iboch.by
Summary
The Institute of Bioorganic Chemistry offers consumers medicinal preparations with antitumor and antiviral activity and initial nucleosides for their creation on the basis of a manufacturing agreement and is looking for partners to conclude a distribution services agreement.
Description
Three new genetically engineered strains producing thermostable nucleoside phosphorylases have been constructed. For the first time, more than a dozen of inaccessible modified nucleosides have been synthesized using these enzymes.

As a result of a targeted search for new biologically important nucleosides, the molecular mechanism of activation of a key biocatalyst for the synthesis of nucleic acid components (purine nucleoside phosphorylase) was established, which provided the identification of a wide range of these compounds with potential activity against cancerous tumors and pathogenic viruses.

The work was carried out jointly with scientists from the Russian Federation, Germany, and the USA and published in Chemistry-A European Journal, 2015, 21, 13401-13419.
Advantages and Innovations
Reducing the cost of the synthesis of biologically active nucleosides due to the use of chemical-enzymatic technologies that have no analogs in the world.
Stage of development
Field tested/evaluated (TRL8)
Comments regarding stage of development
A multienzyme cascade strategy for the synthesis of a wide range of nucleosides for the creation of drugs with antitumor and antiviral activity has been developed and experimentally tested, ready for the purposeful creation on its basis of a new generation of biotechnologies for the formation of compounds of a nucleic nature of the desired design and biological activity.
Funding source
State budged
Internal
IPR status
Exclusive rights
Patents granted
Secret know-how
Comments regarding IPS status
RB Patent No. 19553 "Escherichia coli strain producing pyrimidine - cleoside phosphorylase Thermus thermophilus ".
Sector group
BioChemTech

Client information

Type
R&D institution
Year established
1974
NACE keywords
C.20.59 - Manufacture of other chemical products n.e.c.
C.21.10 - Manufacture of basic pharmaceutical products
C.21.20 - Manufacture of pharmaceutical preparations
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
10-20M
Already engaged in transnational cooperation
Yes
Additional comments
The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Distribution services agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing the medicinal preparations with antitumor and antiviral activity and initial nucleosides for their creation under a manufacturing agreement.

Distributors interested in purchasing the medicinal preparations with antitumor and antiviral activity and initial nucleosides for their creation under a distribution services agreement.
Type and size of partner sought
> 500 MNE
> 500
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University

Attachments

Количество уникальных просмотров в одной сессии: 1314
Статистика ведется с 14.01.2022 14:13:27